The Potential of Cammelia sinensis (Tea Leaves) Active Compound as Alternative Therapy on castrate-resistant prostate cancer (CRPC) with Androgen Receptor Inhibition: In Silico Study
Downloads
Introduction: Prostate cancer is a leading global cause of increased mortality and morbidity in men which can be complicated by castrate-resistant prostate cancer (CRPC). Pharmacological therapy by inhibiting the androgen receptor (AR) can inhibit prostate cancer progression. Tea leaves (Camellia sinensis) are believed to inhibit the prostate cancer progression but the mechanism is still unknown. Therefore, research on the mechanism by in silico study is needed with the AR as target protein.
Methods: The effectivity of tea leaves' active compound to inhibit androgen receptor was evaluated by docking server with abiraterone acetate as a control. The tea leaves' active compounds consist of catechin, epicatechin, epigallocatechin gallate, epigallocatechin, gallate epicatechin, gallocatechin gallate, and gallocatechin
Results: The result showed that epicatechin, epigallocatechin, and gallocatechin have lower free binding energy (ΔG) and high amino acid residue similarity on AR compared with abiraterone acetate. But, it has lower surface interaction compared with abiraterone acetate.
Conclusion: Epicatechin, epigallocatechin, and gallocatechin are predicted to have potential as alternative therapy in CRPC with AR Inhibition.
Scher HI, Solo K, Valant J, et al. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS One 2015; 10: e0139440.
Mochtar CA, Atmoko W, Umbas R, et al. Prostate cancer detection rate in Indonesian men. Asian J Surg 2018; 41: 163–169.
Crowley F, Sterpi M, Buckley C, et al. A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. Res reports Urol 2021; 13: 457–472.
Hirst CJ, Cabrera C, Kirby M. Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. Cancer Epidemiol 2012; 36: e349-53.
Huang Y, Jiang X, Liang X, et al. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett 2018; 15: 6063–6076.
Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014; 6: 167–179.
Crawford ED, Schellhammer PF, McLeod DG, et al. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. J Urol 2018; 200: 956–966.
Hu J, Wang G, Sun T. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol J Int Soc Oncodevelopmental Biol Med 2017; 39: 1010428317692259.
Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76–85.
Lam T, Birzniece V, McLean M, et al. The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training. Sport Med - open 2020; 6: 13.
Gedeborg R, Styrke J, Loeb S, et al. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One 2021; 16: e0255966.
Zhang H, Sun Z, Liu Z, et al. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Future Med Chem 2018; 10: 2855–2875.
Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015; 4: 365–380.
Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 2019; 22: 24–38.
Lassed S, Deus CM, Djebbari R, et al. Protective Effect of Green Tea (Camellia sinensis (L.) Kuntze) against Prostate Cancer: From In Vitro Data to Algerian Patients. Evid Based Complement Alternat Med 2017; 2017: 1691568.
Rosati R, Polin L, Ducker C, et al. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. Clin cancer Res an Off J Am Assoc Cancer Res 2018; 24: 6509–6522.
Siddiqui IA, Asim M, Hafeez BB, et al. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J Off Publ Fed Am Soc Exp Biol 2011; 25: 1198–1207.
Du X, Li Y, Xia Y-L, et al. Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods. Int J Mol Sci; 17. Epub ahead of print Januari 2016. DOI: 10.3390/ijms17020144.
Tan MHE, Li J, Xu HE, et al. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 2015; 36: 3–23.
Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol 2015; 9: 389–397.
Chen J, Sawyer N, Regan L. Protein-protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci 2013; 22: 510–515.
Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health 2019; 37: 288–295.
Kim TJ, Lee YH, Koo KC. Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review. Biomolecules; 11. Epub ahead of print Maret 2021. DOI: 10.3390/biom11040492.
Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med; 8. Epub ahead of print Juni 2018. DOI: 10.1101/cshperspect.a030635.
Copyright (c) 2022 Mega Memory Rahasa Putra, Kurnia Penta Seputra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
